序号 |
标题 |
次数 |
作者 |
发布时间 |
78661 |
HS-(CH2)11-O-Disperse Red 1 十一烷烃硫醇化荧光配体 |
197 |
h |
2024-12-19 |
78662 |
HS-(CH2)16-(EG)2 -N(+)(CH3)2-CH2-COO(-) 二聚乙二醇化十六硫醇 |
144 |
h |
2024-12-19 |
78663 |
cas:103750-03-4,5-Maleimido-pentanoic NHS ester,5-马来酰亚胺戊酸NHS |
146 |
kx |
2024-12-19 |
78664 |
4-Nitrophenyl 2-(pyridin-2-yldisulfanyl)propyl carbonate,抗体药物偶联物(ADC) |
143 |
kx |
2024-12-19 |
78665 |
cas:158913-22-5,SPDP-C6-NHS ester,琥珀酰亚胺基6-[3-(2-吡啶基二硫代)丙酰胺基]己酸酯 |
142 |
kx |
2024-12-19 |
78666 |
perfluorophenyl 4-methyl-4-(pyridin-2-yldisulfanyl)pentanoate,抗体药物偶联物(ADC) |
148 |
kx |
2024-12-19 |
78667 |
cas:663598-61-6,2,5-dioxopyrrolidin-1-yl 4-((5-nitropyridin-2-yl)disulfanyl)pentanoate, ADC试剂 |
120 |
kx |
2024-12-19 |
78668 |
perfluorophenyl 4-(pyridin-2-yldisulfanyl)butanoate, ADC试剂 |
107 |
kx |
2024-12-19 |
78669 |
cas:160580-70-1,perfluorophenyl 3-(pyridin-2-yldisulfanyl)propanoate,抗体药物偶联物(ADC) |
161 |
kx |
2024-12-19 |
78670 |
cas:252554-78-2, Fmoc-Ala-Ser(Psi(Me Me)pro)-OH,(4S)-3-[(2S)-2-[[(9H-芴-9-甲氧基)羰基]氨基]-1-氧代丙基]-2,2-二甲基-4-恶唑烷羧酸 |
173 |
kx |
2024-12-19 |
78671 |
MC-Val-Cit-PAB-Indibulin, cas:2055896-95-0 |
118 |
WYQ |
2024-12-19 |
78672 |
cas:1884578-27-1 ,Alloc-Val-Ala-PAB-PNP,N-[(2-丙烯-1-基氧基)羰基]-L-缬氨酸-N-[4-[[(4-硝基苯氧基)羰基]氧基]甲基]苯基]-L-丙氨酸酰胺 |
145 |
kx |
2024-12-19 |
78673 |
mDPR-Val-Cit-PAB-MMAE(CAS:1491152-26-1) |
121 |
WYQ |
2024-12-19 |
78674 |
2,5-dioxopyrrolidin-1-yl 1-(bicyclo[6.1.0]non-4-yn-9-yl)-3-oxo-2,7,10,13-tetraoxa-4-azahexadecan-16-oate |
120 |
wyh |
2024-12-19 |
78675 |
MC-Val-Cit-PAB-vinblastine(CAS:2055896-92-7) |
123 |
WYQ |
2024-12-19 |
78676 |
2,5-dioxopyrrolidin-1-yl 1-(bicyclo[6.1.0]non-4-yn-9-yl)-3-oxo-2,7,10,13-tetraoxa-4-azahexadecan-16-oate |
112 |
wyh |
2024-12-19 |
78677 |
MC-Val-Cit-PAB-tubulysin5a(CAS:2055896-86-9) |
111 |
WYQ |
2024-12-19 |
78678 |
N-芴甲氧羰基-四聚乙二醇-VAL-ALA-PAB, Fmoc-PEG4-Val-Ala-PAB |
146 |
kx |
2024-12-19 |
78679 |
MC-Val-Cit-PAB-clindamycin(CAS号:1639793-13-7) |
99 |
WYQ |
2024-12-19 |
78680 |
MC-Val-Cit-PAB-carfilzomib,CAS号:2055896-83-6 |
135 |
WYQ |
2024-12-19 |
78681 |
叔丁酯-四聚乙二醇-VAL-ALA-PAB,Boc-PEG4-Val-Ala-PAB |
115 |
kx |
2024-12-19 |
78682 |
MC-Val-Cit-PAB-Auristatin E,CAS号:2055896-77-8 |
136 |
WYQ |
2024-12-19 |
78683 |
MC-Sq-Cit-PAB-Gefitinib(CAS:1941168-63-3) |
195 |
WYQ |
2024-12-19 |
78684 |
HS-(CH2)m-(EG)n -N(+)(CH3)2-CH2-COO(-) 聚乙二醇化直链烷烃硫醇 |
116 |
h |
2024-12-19 |
78685 |
Mal-PEG4-Val-Ala-PAB,马来酰亚胺-四聚乙二醇-VAL-ALA-PAB |
161 |
kx |
2024-12-19 |
78686 |
MC-GGFG-DX8951(CAS:1600418-29-8) |
344 |
WYQ |
2024-12-19 |
78687 |
(HO)2-PO-S-(CH2)6-EG2-OH 硫-(2-羟基六烷-1-基)硫代磷酸酯 |
161 |
h |
2024-12-19 |
78688 |
Au_55_C11EG4Carboxybetaine 金团簇55-羧基甜菜碱 |
173 |
h |
2024-12-19 |
78689 |
(HO)2-PO-S-(CH2)m-COONHS 硫-(2,5-二氧代 - 吡咯烷-1-基氧基羰基)-1-基硫代磷酸 |
130 |
h |
2024-12-19 |
78690 |
2529982-76-9,Azido-PEG4-Val-Ala-PAB,叠氮-四聚乙二醇-VAL-ALA-PAB |
145 |
kx |
2024-12-19 |
78691 |
Au_12_C11EG6 金团簇12-直链烷烃六聚乙二醇 |
183 |
h |
2024-12-19 |
78692 |
cas:863971-17-9 ,MC-Val-Cit-PAB-MMAF,MC-VAL-CIT-PAB-MMAF游离态 |
115 |
kx |
2024-12-19 |
78693 |
CF3-(CF2)5-C2-O-C11-Si(OMe)3 巯基-直链烷烃连接氟化硫醇和硅烷 |
142 |
h |
2024-12-19 |
78694 |
cas:2353409-69-3 , Mal-PEG8-Val-Cit-PAB-MMAE,马来酰亚胺-八聚乙二醇-VAL-CIT-PAB-MMAE |
137 |
kx |
2024-12-19 |
78695 |
cas:2129164-91-4 , DBCO-PEG4-Val-Cit-PAB-MMAE,二苯并环辛炔-四聚乙二醇-VAL-CIT-PAB-MMAE |
178 |
kx |
2024-12-19 |
78696 |
MAL-di-EG-Val-Cit-PAB-MMAF,由ADC连接桥(MAL-di-EG-Val-Cit-PAB)和有效的微管蛋白聚合阻断剂(MMAF, Monomethyl auristatin F)组成 |
145 |
WYQ |
2024-12-19 |
78697 |
MAL-di-EG-Val-Cit-PAB-MMAE,CAS编号:2746391-62-6 |
156 |
WYQ |
2024-12-19 |
78698 |
cas:644981-35-1 , Val-Cit-PAB-MMAE, ADC试剂 |
100 |
kx |
2024-12-19 |
78699 |
cas:2754384-60-4,DBCO-(PEG)3-VC-PAB-MMAE,抗体药物偶联物(ADC) |
184 |
kx |
2024-12-19 |
78700 |
AcLys-PABC-VC-Aur0101(CAS:1438851-17-2) |
134 |
WYQ |
2024-12-19 |
78701 |
反式环辛烯-MMAE,TCO-MMAE, ADC试剂 |
176 |
kx |
2024-12-19 |
78702 |
Hydrazone-doxorubicin,阿霉素-腙键偶联物 |
233 |
WYQ |
2024-12-19 |
78703 |
SPP-DM1(CAS号:452072-20-7)C44H59ClN4O14S2 |
191 |
WYQ |
2024-12-19 |
78704 |
氨基-二聚乙二醇-VG-N-双(一聚乙二醇-叠氮),Amino-PEG2-VG-N-Bis(PEG1-azide) |
110 |
kx |
2024-12-19 |
78705 |
DOTA-NHS ester,羟基琥珀酰亚胺-四氮杂环十二烷四乙酸(CAS号:170908-81-3) |
136 |
WYQ |
2024-12-19 |